George Medicines indicators unique licensing settlement with Bausch Well being to commercialize GMRx2 in Canada, Mexico, Columbia and Central America

George Medicines indicators unique licensing settlement with Bausch Well being to commercialize GMRx2 in Canada, Mexico, Columbia and Central America

• Bausch Well being positive aspects unique rights to single-pill triple mixture remedy for hypertension
• George Medicines receives upfront milestone cost and is eligible for regulatory and business milestones, and a stepped royalty price in licensed territories
• GMRx2 has potential to be the one triple mixture authorized for the therapy of hypertension together with preliminary therapy

London, UK, 13 January 2025 – George Medicines, a late-stage biopharmaceutical firm centered on addressing vital unmet wants in cardiometabolic illness, has entered into an unique licensing and provide settlement with Bausch Well being Firms Inc. (NYSE/TSX:BHC) (‘Bausch Well being’), a worldwide, diversified pharmaceutical firm enriching lives via a relentless drive to ship higher well being outcomes, granting Bausch Well being unique rights to hunt regulatory approval of, and to commercialize, GMRx2 in Canada, Mexico, Columbia and Central America.

GMRx2, George Medicines’ lead pipeline candidate for the therapy of hypertension together with preliminary therapy, is a proprietary single-pill mixture of three best-in-class medicines: telmisartan, amlodipine and indapamide. Developed in ultra-low dose, low-dose, and standard-dose choices, it has the potential to be the one triple mixture authorized for the preliminary therapy of hypertension. The revolutionary formulation is designed for optimum efficacy, security and adherence. With a multi-mechanism method and at decrease dosing than in the present day’s therapies, GMRx2 is designed to ship the synergistic efficacy advantages of a triple remedy whereas sustaining tolerability. 

Beneath the phrases of the licensing settlement, George Medicines receives an upfront milestone cost and is eligible for regulatory and business milestone funds, in addition to a future recurring income stream via a stepped royalty price on gross sales of GMRx2 within the licensed territories. In return, Bausch Well being is granted a license to completely commercialize GMRx2, provided by George Medicines, in Canada, Mexico, Columbia and Central America. Bausch Well being is chargeable for in search of regulatory approval of GMRx2, with help from George Medicines.

Mark Mallon, Chief Government Officer of George Medicines, stated: “This announcement marks a big milestone for George Medicines, and in Bausch Well being we’ve secured a powerful business companion who shares our perception within the potential of GMRx2 to allow extra sufferers to realize higher blood strain management and enhance on present hypertension therapy approaches.”

Cees Heiman, Senior Vice President, Europe and Canada, Bausch Well being, stated: “In Canada, seven and a half million folks, about 1 in 4 adults, stay with hypertension¹, and too many shouldn’t have their situation below management. The clinically-proven efficacy of GMRx2 in comparison with twin combos, coupled with its good tolerability, have the potential to handle key challenges in present hypertension therapy approaches. This partnership with George Medicines underscores our dedication to ship higher well being outcomes for sufferers.”

Fernando Zarate, Vice President, Latin America, Bausch Well being, stated: “GMRx2 is a important innovation that we imagine can meaningfully advance cardiovascular care in Mexico, Colombia and Central America. Whereas prevalence of hypertension stays excessive within the area, its therapy and management is low². In GMRx2 we’ve a possibility to alter that.”

Globally, many recognized hypertension sufferers aren’t presently attaining enough blood strain (BP) management as a result of they’re on insufficient remedy, aren’t receiving the proper mixture of medicines on the proper doses or aren’t taking their therapy as prescribed. With the most recent skilled tips from the European Society of Cardiology³ recommending decrease goal BP ranges and early use of mixture remedy, an efficient, low-dose, single-pill triple mixture with good tolerability offers a possibility to considerably advance the administration of hypertension.

GMRx2 is backed by a complete medical improvement program, together with two pivotal Part III research, revealed in 2024 within the Journal of the American College of Cardiology⁴ and The Lancet⁵, demonstrating GMRx2 considerably lowered BP and improved BP management charges, when put next towards twin remedy and towards placebo. The triple mixture was additionally investigated within the Nigerian VERONICA trial⁶, which in contrast GMRx2 with present, normal of care and reported higher BP reducing and management amongst these receiving GMRx2. In all trials, tolerability was good, with no improve in withdrawal from therapy as a consequence of adversarial occasions. A worldwide trial investigating the potential of GMRx2 for the prevention of stroke in individuals who have had intracerebral hemorrhage (essentially the most extreme sort of stroke) is ongoing⁷.

GMRx2 has not obtained regulatory approval for business use in any nation. A New Drug Software (NDA) to the US Meals and Drug Administration (FDA) in search of US approval of GMRx2 for the therapy for hypertension, together with initiation of therapy, is ongoing with a Prescription Drug Person Payment Act (PDUFA) aim date of 5 June 2025. Regulatory submissions in different territories are anticipated in 2025.

George Medicines is an impartial spin-out firm from The George Institute for International Well being, one of many world’s main medical analysis institutes with a give attention to addressing international well being inequity. The Firm is backed by George Well being, the business arm of The George Institute, and Brandon Capital, Australia’s main life sciences enterprise capital agency.

Ends

References:

1. Hypertension Canada Annual Report https://hypertension.ca/wp-content/uploads/2024/10/HC-2024-Annual-Report-Final.pdf)
2. Prevalence, Consciousness, Therapy, and Management of Hypertension within the Southern Cone of Latin America; Am J Hypertens; doi: 10.1093/ajh/hpw092 https://academic.oup.com/ajh/article/29/12/1343/2708296
3. 2024 ESC Pointers for the administration of elevated blood strain and hypertension; European Coronary heart Journal, Quantity 45, Concern 38, 7 October 2024, Pages 3912–4018, https://doi.org/10.1093/eurheartj/ehae178
4. Rodgers A, Salam A, Schutte AE, . . .Whelton P. Efficacy and Security of a Novel Low-Dose Triple Single-Capsule Mixture In contrast With Placebo for Preliminary Therapy of Hypertension. Journal of the American School of Cardiology. 2024;0(0). doi:10.1016/j.jacc.2024.08.025
5. Efficacy and security of a novel low-dose triple single-pill mixture, in contrast with twin combos for therapy of hypertension; The Lancet; doi: 10.1016/S0140-6736(24)01744-6
6. Ojji DB, Salam A, Sani MU, . . .Rodgers A. Low-dose triple-pill vs standard-care protocols for hypertension therapy in Nigeria: a randomized medical trial. doi:10.1001/jama.2024.18080. JAMA. 2024.10.1001/jama.2024.18080
7. TRIDENT: Triple remedy prevention of Recurrent Intracerebral Illness EveNts Trial

About George Medicines

George Medicines is a late-stage biopharmaceutical firm addressing vital unmet want within the therapy of cardiometabolic illnesses with revolutionary combos of best-in-class present remedies, designed for optimum efficacy and security.

Combining best-in-class molecules from present medicines in novel low-dose formulations, George Medicines is creating revolutionary and proprietary remedies to be extra efficacious, safer and accessible than presently out there therapy choices. These multi-mechanism, single-pill combos supply the potential to carry vital enhancements in medical outcomes and remedy adherence in sufferers with cardiometabolic issues, together with hypertension and diabetes, every of which stay the main causes of untimely dying and incapacity worldwide.

For extra data, please go to www.george-medicines.com.

Media contacts

ICR Healthcare
David Daley, Lindsey Neville, Tom Daniel
[email protected]; Tel: +44 (0) 203 709 5700